Top Markets
Coin of the day
Antibe Therapeutics Inc. Antibe Therapeutics Inc.

Antibe Therapeutics Inc.

ATE
Pozycja w akcjach #32097
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Cena akcji
$0.21483059
Ostatnia synchronizacja: 2024-05-07
Kapitalizacja rynkowa
$11.13M
Zmiana (1 dzień)
0.34%
Zmiana (1 rok)
0.00%
Kraj
CA
Handel Antibe Therapeutics Inc. (ATE)

Kategoria

Historia ceny akcji dla Antibe Therapeutics Inc. (ATE)
Najwyższa cena zamknięcia: $0.21 dnia 2024-05-01

Najniższa cena zamknięcia: $5.29 dnia 2013-06-01
Historia cen akcji firmy Antibe Therapeutics Inc. od 2013 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2024 -64.54%
2023 70.18%
2022 -33.02%
2021 -82.13%
2020 -5.82%
2019 63.59%
2018 69.29%
2017 -9.13%
2016 -2.14%
2015 -69.92%
2014 -18.37%
2013 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$110.69 -15.03%
US
$331.82 -13.05%
US
$90.44 -2.55%
IE
$51.45 -50.08%
US
$90.82 15.99%
US